FDA OKs Stem Cell Therapy to Reduce Infection Risk
The agency called the approval of omidubicel "an important advance" for patients with blood cancer who are undergoing allogeneic umbilical cord blood stem cell transplants.
FDA Approvals
source https://www.medscape.com/viewarticle/990896?src=rss
FDA Approvals
source https://www.medscape.com/viewarticle/990896?src=rss
Comments
Post a Comment